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ABSTRACT
The benefit of zinc for the treatment of diarrhoea in a cluster-randomized trial of children, aged 3-59 
months, living in rural Bangladesh was previously reported. Here, the benefits of zinc stratified by age—3-5 
months, 6-11 months, and 12-59 months—are reported. Although the sample sizes in the stratified groups 
were too small to detect statistical significance in the 3-5-month and 6-11-month age-groups, the trends 
suggest that there may be a benefit of zinc for the treatment of diarrhoea on the duration of diarrhoea and 
on subsequent morbidity and mortality. Additional research is needed to better understand the effect of 
zinc for the treatment of diarrhoea among infants aged less than six months.   
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INTRODUCTION
Zinc is an essential micronutrient for human 
growth and immune function (1). When given as 
an adjunct therapy for the treatment of diarrhoea, 
zinc decreases the duration and severity of the epi-
sode (2,3). In addition, supplementation of zinc for 
10-14 days given during a diarrhoea episode has 
been shown to decrease diarrhoea and acute lower 
respiratory infections (ALRIs) in the 2-3 months 
following the episode (2,4).  
The World Health Organization recommends 10-
14 days of zinc for the management of diarrhoea 
among children aged less than five years, in addi-
tion to oral rehydration solution (ORS) (5). Data 
supporting zinc for the treatment of diarrhoea 
is extensive for children aged six months to five 
years. However, only two studies have been con-
ducted exclusively among infants aged less than 
six months and found no effect on the diarrhoea 
episode or on subsequent morbidity (6-8).
Of trials that have enrolled infants as young as three 
months, a few have stratified by age, and none has 
categorized  the  differences  between  infants  aged 
less than six months and those aged >6 months. 
We previously reported the results of a cluster-ran-
domized trial of zinc supplementation for the treat-
ment of diarrhoea that included 11,772 child-years 
of observation (2). Here, we present the effects of 
zinc on the duration of diarrhoea, incidence, hos-
pitalizations, and mortality in a stratified analysis 
of infants aged 3-5 months and 6-11 months and 
compare these results with those observed in chil-
dren aged 12-59 months.    
MATERIALS AND METHODS
Study side and study subjects
Thirty areas under the community health worker 
(CHW) were randomized to introduce zinc supple-
mentation (20 mg of zinc acetate per day for 14 
days), in addition to ORS for the treatment of diar-
rhoea or ORS alone, the standard of care at the time 
of the study. The details of the study design, ran-
domization procedure, and follow-up have been 
previously reported (2). Briefly, we enrolled children, 
aged 3-47 months, living in the rural Matlab field 
area of the International Centre for Diarrhoeal Dis-
ease Research, Bangladesh (ICDDR,B) at the start of 
the study. Children living in the intervention and 
control villages continued to be enrolled as they Fischer Walker CL et al. Zinc therapy for diarrhoea among infants
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reached three months of age and were included in 
follow-up until the age of 59 months. All children 
were visited once every two months to collect data 
on diarrhoea (one-week recall) and ALRI morbidi-
ty (two-week recall). Diarrhoea was defined as >3 
loose, liquid, or watery stools in 24 hours. ALRI was 
diagnosed if the infant had reported cough, difficult 
breathing, and rapid breathing or chest in-drawing. 
A random sample of 1,252 diarrhoea episodes was 
followed up to determine the duration of the epi-
sode. However, the total sample among infants aged 
3-5 months was quite small because of the narrow 
age band and the overall lower rates of diarrhoea 
among infants aged less than six months. All hos-
pitalizations were recorded from the Matlab Health 
Research Centre of ICDDR,B, and each child death 
from the study villages was identified by an ongo-
ing health and demographic surveillance system. 
As this was a community-based study and zinc was 
only available for the treatment of diarrhoea, only 
children with a diarrhoea episode since the start of 
the study would have received zinc.
Consent was obtained from all participating vil-
lages during community meetings to explain the 
study.  Individual  informed  consent  was  also  ob-
tained from parents of surveyed children prior to 
partaking in a survey. The Ethical Review Commit-
tee of ICDDR,B approved the study design and con-
sent procedures.  
Statistical methods
Selected characteristics of infants at enrollment were 
compared between those living in intervention ver-
sus comparison clusters. In age-stratified analyses, 
the duration of diarrhoea was compared between 
infants living in the intervention and comparison 
clusters using individual-level Student’s t-tests and 
Cox’s proportional hazards ratios adjusted for age, 
sex, birth-order, and size of household homestead 
land area (9). Incidence rates of diarrhoea and ALRI 
were calculated by dividing the periods observed 
with diarrhoea or ALRI by the total periods of obser-
vation (x 100 child-years). Rates of hospitalizations 
were calculated by dividing the total admissions by 
the number of child-years observed (x 100 child-
years). Rates of non-injury deaths were calculated 
by dividing the number of deaths by the number 
of child-years observed (x 1,000 child-years). The 
differences in mean rates and corresponding con-
fidence intervals between children living in the in-
tervention and the comparison clusters were then 
calculated  using  cluster-level  t-test  analyses.  All 
analyses were performed with the Stata software 
(version 9.0) (9).  
RESULTS
Age, sex, and birth-order were similar between 
children living in the intervention and those liv-
ing in the comparison clusters at the start of the 
study among all children (data previously present-
ed) and among age-stratified subgroups (2). In a 
subsample of active diarrhoea episodes, a trend to-
wards a benefit of zinc on the duration of diarrhoea 
was observed among infants aged 3-5 months (the 
mean difference 1.6 days), although the benefit of 
zinc on the duration of diarrhoea was only statis-
tically significant among older children (p<0.001 
and hazard ratio=0.77, 95% confidence interval: 
0.68-0.87 if >12 months) (Table 1). There was a 
non-statistically  significant  trend  towards  lower 
rates of ALRI incidence among infants in each age-
stratum living in the zinc intervention compared 
to the comparison clusters as observed from cross-
sectional community surveys (Table 2). The rates 
of diarrhoea incidence were lower among children 
living in the intervention clusters compared to the 
comparison clusters for those aged 6-11 months 
(the difference in incidence rate [IR]=3.36; p<0.05) 
and aged >12 months (the difference in IR=2.86; 
p<0.05). There was a trend towards lower rates of 
ALRI and diarrhoea hospitalizations among in-
fants aged 3-5 months and 6-11 months living in 
the intervention clusters vs the comparison clus-
Table 1. Duration of diarrhoea episodes* by intervention group among a sample of active diar-
rhoea cases in Matlab, Bangladesh
Age (months)
Intervention Comparison
No. Days No. Days p value‡ Hazard ratio (95% CI)
3-5 
6-11
<12
  16
  84
100
6.4+4.3†
5.8+4.6
5.9+4.5
  22
  83
105
8.0+6.3
6.8+4.9
7.1+5.2
0.3865
0.1757
0.0794
0.76 (0.39–1.47)
0.82 (0.61–1.12)
0.80 (0.61–1.06)
12-59  520 4.5+3.5 527 5.7+4.5 <0.001 0.77 (0.68–0.87)
*>3 loose or watery stools in 24 hours; †Data are presented as mean+standard deviation; ‡Differences in 
means between intervention and comparison assessed by Student’s t-test analysis; CI=Confidence interval Fischer Walker CL et al. Zinc therapy for diarrhoea among infants
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ters and a statistically significant reduction among 
children aged >12 months. Children living in the 
zinc clusters in each age stratum had lower rates of 
non-injury mortality compared to children living 
in the comparison clusters, although these were 
not statistically significant when stratified by age 
(Table 3).    
DISCUSSION
In this stratified analysis of children enrolled in 
our large cluster-randomized effectiveness trial, we 
observed a trend towards a benefit of zinc for diar-
rhoea on the duration of diarrhoea and subsequent 
morbidity and mortality in each age-stratum (3-5 
months,  6-11  months,  and  12-59  months).  The 
sample sizes for this study were originally calcu-
lated to detect a 33% difference in hospitaliza-
tion rates and a one-day difference in the dura-
tion of diarrhoea episodes among children aged 
3-59 months in the intervention clusters vs the 
comparison clusters. Although the original study 
design was not powered to detect statistically sig-
nificant differences for the main outcome mea-
sures  when  stratified  by  age,  we  conducted  this 
secondary analysis because there have been only 
two studies of zinc for the treatment of diarrhoea 
that enrolled infants aged less than six months. 
Since  these  two  recently-published  randomized 
placebo-controlled trials of infants aged less than 
six months found no difference in the duration or 
severity of diarrhoea between infants who received 
zinc or those who received placebo (6,7), we felt it 
important to determine if the same trend among 
young infants was observed in this large cluster-
randomized trial. 
Unlike the two previously-published studies, 
we observed a trend for shorter duration of diar-
rhoea among infants in the zinc clusters which 
was similar to that observed in older children. In 
our community-based study, infants living in the 
zinc clusters were treated with 20 mg of zinc for 14 
days. Brooks et al. did not observe any effect of zinc 
on the duration of diarrhoea among Bangladeshi 
hospitalized male infants, aged 1-6 month(s), who 
received either 5 mg or 20 mg of zinc per day dur-
ing hospitalization (6). Fischer Walker et al. did not 
observe an effect of zinc on the duration of acute 
diarrhoea among Ethiopian, Indian and Pakistani 
infants, aged 1-5 months, who received 10 mg of 
zinc per day for 14 days upon presentation to an 
outpatient clinic (7). It is possible that the differ-
ences in populations and dose may account for the 
variation in results. Although zinc has been shown 
to benefit hospitalized children (10,11), young in-
fants with episodes requiring hospitalizations may 
have additional complications that mask the ben-
efit of zinc supplementation. The current recom-
mendations of WHO call for 10 mg of zinc per day 
for 10-14 days for infants aged 1-5 month(s) as was 
Table 3.  Non-injury deaths rates among intervention and control clusters in Matlab, Bangladesh
Age stratification for non- 
injury deaths
Intervention Comparison Differences in mean rates
(95% CI)*
3-5 months
   Child-years observed
   Non-injury deaths
   Non-injury death rate
328.5
3
9.1
342.3
8
24.7 15.6 (-5.3–36.4)
6-11 months
   Child-years observed
   Non-injury deaths
   Non-injury death rate
690.6
6
8.7
707.9
7
9.9 1.2 (-8.5–10.9)
<12 months
   Child-years observed
   Non-injury deaths
   Non-injury death rate
1,019.1
9
8.8
1,032.2
15
14.5 5.7 (-4.0–15.4)
12-59 months
   Child-years observed
   Non-injury deaths
   Non-injury death rate
4,846.9
4
0.8
4,964.8
12
2.4 1.6 (-0.1–3.3)
*Based on cluster-level t-test analysis. The differences in mean rates expressed per 1,000 child-
years of observation Fischer Walker CL et al. Zinc therapy for diarrhoea among infants
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given in the study by Fischer Walker et al. (7). Given 
the lack of effect observed in this study with 10 mg 
of zinc per day and our positive trend giving 20 mg 
per day, it is possible that the 20-mg dose recom-
mended for older children may also be beneficial 
for young infants. A 20-mg dose has been shown 
to be safe (6). However, additional research may be 
important to verify these safety results and further 
evaluate possible efficacy among infants aged less 
than six months.   
Zinc for the treatment of diarrhoea has been shown 
to decrease subsequent morbidity due to diarrhoea 
and ALRI in older children but not among infants 
aged less than six months (4,8). Similar to what 
has been previously reported, we observed a sig-
nificant benefit of zinc for diarrhoea on the future 
incidence of diarrhoea only among children aged 
>6 months. However, this trial is different from the 
previously-published efficacy trial in this age-group 
because, in this study, data on morbidity were col-
lected  from  random  surveys  which  might  have 
included infants who had not yet been treated for 
a diarrhoea episode (the only opportunity to have 
received zinc) at the time of the survey.  
The benefit of zinc on hospitalization rates was 
only statistically significant among children aged 
>12 months, although the absolute differences in 
rates were not the greatest in this age-group, sug-
gesting that the lack of observed effect among these 
infants may be a result of inadequate sample size. 
We previously reported an overall 51% reduction 
in mortality among infants living in zinc clusters 
(2). Although the statistical significance was lost 
in the stratified analyses, the trend among infants 
aged less than six months was consistent with the 
overall reduction in morbidity.   
Although young infants typically experience fewer 
episodes of diarrhoea than older children, it is of 
public-health importance to understand if zinc is ef-
fective for the management of diarrhoea in infants 
aged less than six months. To date, randomized ef-
ficacy trials have not demonstrated a benefit or risk 
of zinc for the management of diarrhoea among 
infants aged less than six months. Although the 
results of this stratified analysis lacked the power 
to demonstrate a statistically significant effect, the 
reductions we observed were clinically similar to 
those we reported in all children and suggest that 
young infants may benefit from zinc therapy given 
at 20 mg per day for the management of diarrhoea. 
Additional research and analyses of existing data 
are needed to determine if this trend has been ob-
served in other large trials which included young 
infants aged less than six months.
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